Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.

Brendan M Everett Robert J Smith William R Hiatt

N Engl J Med

From Harvard Medical School and Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital - both in Boston (B.M.E.); the Department of Medicine, Alpert Medical School, and the Department of Health Services, Policy, and Practice, School of Public Health, Brown University; and Ocean State Research Institute, Providence VA Medical Center - all in Providence, RI (R.J.S.); and the Department of Medicine, Division of Cardiology, University of Colorado School of Medicine, and CPC Clinical Research - both in Aurora (W.R.H.). All three authors participated as voting members of the FDA Endocrinologic and Metabolic Drugs Advisory Committee meeting on alirocumab, and Drs. Smith and Hiatt participated as voting members of the Advisory Committee meeting on evolocumab.

Published: October 2015

Download full-text PDF	Source
http://dx.doi.org/10.1056/NEJMp1508120	DOI Listing

Publication Analysis

Top Keywords

reducing ldl

ldl pcsk9

pcsk9 inhibitors--the

inhibitors--the clinical

clinical benefit

benefit lipid

lipid drugs

reducing

pcsk9

inhibitors--the

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!